Metagenomi Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
MGX$0.70-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2025 and 2024
Balance Sheets
(In thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $41,722 | $27,386 |
| Available-for-sale marketable securities | 119,077 | 220,921 |
| Accounts receivable | 305 | 1,257 |
| Prepaid expenses and other current assets | 4,434 | 8,396 |
| Total current assets | 165,538 | 257,960 |
| Property and equipment, net | 12,288 | 17,740 |
| Long-term investments | 2,154 | 3,447 |
| Operating lease right-of-use assets | 35,094 | 39,917 |
| Other assets | 836 | 287 |
| Restricted cash | 5,193 | 5,248 |
| Total assets | $221,103 | $324,599 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,489 | $533 |
| Accrued expenses and other current liabilities | 6,719 | 8,422 |
| Current portion of operating lease liabilities | 6,025 | 5,592 |
| Deferred revenue | 8,700 | 22,762 |
| Total current liabilities | 22,933 | 37,309 |
| Non-current portion of operating lease liabilities | 34,632 | 40,186 |
| Deferred revenue, non-current | 2,989 | 10,237 |
| Other non-current liabilities | 1,953 | 2,010 |
| Total liabilities | 62,507 | 89,742 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value; 10,000,000 shares authorized and zero shares issued and outstanding | — | — |
| Common stock: $0.0001 par value; 500,000,000 shares authorized; 37,620,668 and 37,418,470 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 4 | 4 |
| Additional paid-in capital | 469,202 | 457,146 |
| Accumulated other comprehensive income | 260 | 709 |
| Accumulated deficit | (310,870) | (223,002) |
| Total stockholders’ equity | 158,596 | 234,857 |
| Total liabilities and stockholders’ equity | $221,103 | $324,599 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.